Clinical Trial Update: Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial compared the efficacy and safety of a glycopyrronium/formoterol fumarate fixed-dose combination versus umeclidinium/vilanterol over 24 weeks in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Glycopyrronium/Formoterol Fumarate Fixed-dose Combination (glycopyrronium/formoterol fumarate)
• Umeclidinium/Vilanterol Fixed-dose Combination (umeclidinium/vilanterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease COPD | Phase 3 | Status: COMPLETED | Results posted: 2019-05-22